Targeting the CD20 and CXCR4 Pathways in Non Hodgkin ...clincancerres.aacrjournals.org/content/clincanres/early/2013/05/10/... · 1 Targeting the CD20 and CXCR4 Pathways in Non Hodgkin
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Targeting the CD20 and CXCR4 Pathways in Non Hodgkin Lymphoma
with Rituximab and high affinity CXCR4 antagonist BKT140
Katia Beider1, Elena Ribakovsky1, Michal Abraham3, Hanna Wald3, Lola Weiss2,
Evgenia Rosenberg1, Eithan Galun2, Abraham Avigdor1, Orly Eizenberg3, Amnon
Peled2,3 and Arnon Nagler1.
1Hematology Division, BMT and CBB, Sheba Medical Center, Tel-Hashomer,
Israel. 2Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University
Running title: Non Hodgkin Lymphoma and CXCR4 Key words: CXCR4, CD20, NHL, rituximab, microenvironment Financial support: Scientific grant from Hoffman La Roche to AN, and Sarousy Foundation grant to AN
Conflict of interest: MA, HW and OE are employee of Biokine Therapeutics; AP and AN serve as consultant in Biokine Therapeutics. The remaining authors declare no competing financial interests. Text word count: 4823 Number of figures: 6
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
1. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992;52(19 Suppl): 5432s-40s. 2. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91(5): 1644-52. 3. White CA. Rituximab immunotherapy for non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1999;14(4): 241-50. 4. Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010;2(1): 14-9. 5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12(2): 121-7. 6. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 1994;91(6): 2305-9. 7. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107(5): 1761-7. 8. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382(6592): 635-8. 9. Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 1998;10(3): 179-85. 10. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A 1998;95(16): 9448-53. 11. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393(6685): 595-9. 12. Peled A, Grabovsky V, Habler L, Sandbank J, Arenzana-Seisdedos F, Petit I, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999;104(9): 1199-211. 13. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283(5403): 845-8. 14. Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999;13(12): 1954-9. 15. Bradstock KF, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb DJ. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 2000;14(5): 882-8. 16. Dialynas DP, Shao L, Billman GF, Yu J. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood. Stem Cells 2001;19(5): 443-52. 17. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2(12): 927-37. 18. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64(8): 2817-24.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
19. Shen W, Bendall LJ, Gottlieb DJ, Bradstock KF. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001;29(12): 1439-47. 20. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96(8): 2655-63. 21. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94(11): 3658-67. 22. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009;113(19): 4604-13. 23. Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 2010;151(2): 167-78. 24. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009;113(24): 6206-14. 25. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113(18): 4341-51. 26. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824): 50-6. 27. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167(8): 4747-57. 28. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6(9): 3530-5. 29. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425(6955): 307-11. 30. Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 2004;19(1): 299-309. 31. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14(3): 171-9. 32. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004;104(2): 502-8. 33. Lopez-Giral S, Quintana NE, Cabrerizo M, Alfonso-Perez M, Sala-Valdes M, De Soria VG, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004;76(2): 462-71. 34. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006;5(12): 3113-21. 35. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106(5): 1824-30. 36. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113(24): 6215-24. 37. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2010;25(8): 1314-23. 38. Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62(11): 3106-12. 39. Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L, et al. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 2005;105(3): 931-9. 40. O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 2012;119(7): 1717-25. 41. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253(3): 877-82. 42. Lili J, Yuchen S, Zhengtao W. The chemokine SDF-1alpha suppresses fibronectin-mediated in vitro lymphocytes adhesion. Mol Cells 2006;22(3): 308-13. 43. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007;25(9): 2158-66. 44. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011;39(3): 282-92. 45. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of Cu-AMD3100. Mol Imaging Biol 2012;14(1): 106-14. 46. Mancuso P, Calleri A, Antoniotti P, Quarna J, Pruneri G, Bertolini F. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer 2010;10: 644. 47. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008;19(7): 1331-5.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015
Published OnlineFirst May 1, 2013.Clin Cancer Res Katia Beider, Elena Ribakovsky, Michal Abraham, et al. BKT140Lymphoma with Rituximab and high affinity CXCR4 antagonist Targeting the CD20 and CXCR4 Pathways in Non Hodgkin
Updated version
10.1158/1078-0432.CCR-12-3015doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2013/05/10/1078-0432.CCR-12-3015To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 1, 2013; DOI: 10.1158/1078-0432.CCR-12-3015